Cargando…
AKR1C3 Converts Castrate and Post-Abiraterone DHEA-S into Testosterone to Stimulate Growth of Prostate Cancer Cells via 5-Androstene-3β,17β-Diol
Androgen receptor signaling inhibitors (ARSI) are used to treat castration-resistant prostate cancer (CRPC) to stop a resurgence of androgen receptor (AR) signaling. Despite early success, patients on ARSIs eventually relapse, develop drug resistance, and succumb to the disease. Resistance may occur...
Autores principales: | Detlefsen, Andrea J., Mesaros, Clementina A., Duan, Ling, Penning, Trevor M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508215/ https://www.ncbi.nlm.nih.gov/pubmed/37772993 http://dx.doi.org/10.1158/2767-9764.CRC-23-0235 |
Ejemplares similares
-
RF03 | PMON296 Insulin-induced AKR1C3 Metabolizes Classical and 11-oxygenated Androgens in a Model of PCOS Adipocytes
por: Mesaros, Clementina, et al.
Publicado: (2022) -
Epoxidation and Reduction of DHEA, 1,4,6-Androstatrien-3-one and 4,6-Androstadien-3β,17β-diol
por: Ma, Eunsook, et al.
Publicado: (2005) -
SUN-361 Cultured Murine Osteoblasts Convert DHEA to Testosterone
por: Clines, Katrina L, et al.
Publicado: (2020) -
Intratumoral Treatment with 5-Androstene-3β, 17α-Diol Reduces Tumor Size and Lung Metastasis in a Triple-Negative Experimental Model of Breast Cancer
por: Ruiz Manzano, Rocío Alejandra, et al.
Publicado: (2022) -
The neuro-steroid, 3β androstene 17α diol exhibits potent cytotoxic effects on human malignant glioma and lymphoma cells through different programmed cell death pathways
por: Graf, M R, et al.
Publicado: (2007)